Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;19(2):e202300220.
doi: 10.1002/prca.202300220. Epub 2025 Jan 26.

The Contribution and Perspectives of Proteomics to Epithelial Ovarian Cancer

Jiayu Pei  1 , Haifeng Qiu  2 , Wenjia Wang  1 , Yulu Wang  1 , Min Wang  2 , Dian Wang  2 , Jing Li  1 , Yanru Qin  1
Affiliations
Review

The Contribution and Perspectives of Proteomics to Epithelial Ovarian Cancer

Jiayu Pei et al. Proteomics Clin Appl. 2025 Mar.

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy which mainly consists of serous, mucinous, clear cell, and endometrioid subtypes. Due to the lack of classic symptoms at an early stage, EOC usually presented as advanced tumors with local and/or distant metastasis. Although a large portion of EOC was initially platinum-sensitive, most patients would acquire resistance to common chemotherapeutic agents. These aforementioned issues lead to a challenge for clinical treatments and unsatisfying outcomes. Previous studies have demonstrated the genetic features of EOC are hard to target and the alterations at DNA and RNA levels are not fully represented at the protein expression profiles which made it more complex. In recent years, a panel of studies attempted to explore the key proteins involved in the development and progression of EOC using high-throughput proteomic technologies. We herein summarized them to provide a full view of this topic.

Keywords: biomarkers; drug resistance; epithelial ovarian cancer; proteomics; screening.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. M. Liu and J. Peng, “A Meta‐Analysis of the Effect of Pelvic and Para‐Aortic Lymph Node Dissection on the Prognosis of Patients With Endometrial Cancer,” Biotechnology & Genetic Engineering Reviews 40 (2023): 1–19, https://doi.org/10.1080/02648725.2023.2202989.
    1. C. Xia, X. Dong, H. Li, et al., “Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants,” Chinese Medical Journal 135 (2022): 584–590, https://doi.org/10.1097/CM9.0000000000002108.
    1. Q. Yang, C. Zhang, Y. Ren, et al., “Genomic Characterization of Chinese Ovarian Clear Cell Carcinoma Identifies Driver Genes by Whole Exome Sequencing,” Neoplasia (New York, NY) 22 (2020): 399–430, https://doi.org/10.1016/j.neo.2020.06.002.
    1. A. Yokoi, Y. Yoshioka, Y. Yamamoto, et al., “Malignant Extracellular Vesicles Carrying MMP1 mRNA Facilitate Peritoneal Dissemination in Ovarian Cancer,” Nature Communications 8 (2017): 14470, https://doi.org/10.1038/ncomms14470.
    1. R. Jiang, J. Zhu, J. W. Kim, et al., “Study of Upfront Surgery versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer, SGOG SUNNY (SOC‐2) Trial Concept,” Journal of Gynecologic Oncology 31 (2020): e86, https://doi.org/10.3802/jgo.2020.31.e86.

MeSH terms

Substances

LinkOut - more resources